In this detailed critique of the study proposing using RNA-seq from tumor-educated platelets (TEP) as a 'liquid biopsy' source [1], several flawed assumptions leave little biological basis behind the statistical computations. First, there is no supporting evidence provided for the FFPE based classification of METoverexpression and EGFR mutation on tumor-tissues. Considering that raw reads of MET expression in a subset of healthy [N=21, mean=112, sd=77] and NSCLC [N=24, mean=11, sd=12] samples (typically with millions of reads) translates into over-expression in reality, providing the data for such computations is vital for future validation. A similar criticism applies for classifying samples based on EGFR mutations (the study uses only exon 20 and 21 from a wide range of possible mutations) with negligible counts
Introduction
Tumor tissue biopsy, the gold standard for cancer diagnostics, pose challenges that include access to the tumor, quantity and quality of tumoral material, lack of patient compliance, repeatability, and bias of sampling a specfic area of a single tumor [6] . This has resulted in a new medical and scientific paradigm defined by minimal invasiveness, high-efficiency, low-cost diagnostics [7] , and, whenever possible, personalized treatment based on genetic and epigenetic composition [8] . The presence of fragmented DNA in the cell-free component of whole blood (cfDNA) [9] , first reported in 1948 by Mandel and Metais, has been extensively researched for decades, with extremely promising results in certain niches [10] . Additionally, cfDNA derived from tumors (ctDNA) [11] have tremendous significance as a cancer diagnostic tool [12] , and for monitoring responses to treatment [13] . However, detection of ctDNA, and differentiation with cfDNA, remains a challenge due the low amounts of ctDNA compared to cfDNA [14] .
Recently, tumor-educated blood platelets (TEP) were proposed as an alternative source of tumor-related biological information [1, 15] . The hypothesis driving the potential diagnostic role of TEPs is based on the interaction between blood platelets and tumor cells, subsequently altering the RNA profile of platelets [16, 17] . The study showed using RNA-seq data that tumor-educated platelets (TEP) can distinguish 228 patients with localized and metastasized tumors from 55 healthy individuals with 96% accuracy [1] . As validation, this study reported significant over-expression of MET genes in non-small cell lung carcinoma (NSCLC), and HER2/ERBB2 [18] genes in breast cancer, which are well-established biomarkers. Also, using a set of 1072 genes, the study reported >95% accuracy in pan-cancer diagnostics (Fig 1 in [1]) .
Here, the TEP-study is refuted based on the absence of any kind of biological relevance to the discriminator set of genes other than varying numbers, which could be assigned to a number of reasons. First, the almost negligible amounts of MET/EGFR reads in the NSCLC samples is demonstrated. The critiques can be enumerated as:
1. There is no supporting evidence for FFPE based classification of MET-overexpression and EGFR mutants.
2. Inclusion of genes with such low counts, like TRAT1.
3. Genes with high reads, like F13A1, which can only be bona-fide platelet genes.
Contradictory results:
Erroneous and ambiguous classification of MET-overexpression and EGFR mutations:
Both MET-overexpression and EGFR mutations use FFPE, which are solutions 'designed to meet the challenges of analyzing degraded or limited genomic material' (https://www.illumina.com/science/education/ffpesample-analysis.html). 'Overexpression of MET protein in tumor tissue relative to adjacent normal tissues occurs in 25-75% of NSCLC and is associated with poor prognosis' https://www.mycancergenome.org/content/disease/lung-cancer/met/343/. However, in the TEP-study only 13% (8 out of 60) are MET+, which seems too low (Table S1 ). Further, the classification "MET WT" is not clearly defined. The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/146134 doi: bioRxiv preprint first posted online Jun. 5, 2017; for EGFR mutations, supporting FFPE studies [20] . However, they provide a complete list of the amplicons in Table 1 , a meticulous classification of the EGFR mutations found in Table 4 , and macrodissection showing EGFR mutation status in Fig 1 [20] . This includes EGFR exons 18 and 19 as well, which have been missed out in the TEP study ('EGFR (exon 20 and 21) amplicon deep sequencing strategy ($5,0003 coverage) on the Illumina Miseq platform using prospectively collected blood samples of patients with localized or metastasized cancer' [1] ).
To summarize, for MET-overexpression classification (with an exceptionally low occurrence compared to known values) the FFPE data has not been provided. In the case of EGFR classification in the TEP-study, it clearly is erroneous, since only a subset of known mutations were used. It is vital to know that the classification has been done properly, before providing statistics based on surrogate biomarkers.
Genes with such low reads, like TRAT1, can not be discriminators: 14 24 5 11 9 45 1 5 11 9 12 5 2 34 3 7 42 6 16 12 2 5 2], it is obvious that genes with small counts (say in the hundreds) can not be discriminators.
Yet, TRAT1 is one such gene in the set of 1072 genes that has been shown to give >95% accuracy as a pan-cancer diagnostic (Fig 1 in [1] , Table S4 Genes with high counts, like F13A1, are bona-fide platelet genes, and can not be discriminator genes: Platelets have no nucleus, and are bootstrapped with their mRNA during origination [21] . Phillip Sharp and Richard Roberts discovered splicing in 1977, for which they were awarded the Nobel Prize in 1993. Spliceosomes were assumed to be nucleus-confined till 2005, when it was a surprising find that 'primary human platelets also contain essential spliceosome factors including small nuclear RNAs, splicing proteins, and endogenous pre-mRNAs'' [2] . The 30 year lag in this realization probably indicates that splicing can not be a dominant effect in platelets, and the causal agent of very large differences in counts. So, it would be speculative to implicate splicing to account for the difference in F13A1 counts, and assign it discriminatory status, without proper experimental proof. For example, Zucker, et al., 2017 have shown that 'that F11 is present in platelets as pre-mRNA and is spliced upon platelet activation' [3] . In addition to demonstrating the same for F13A1, any study using this gene as a discriminator ought to show differential counts in TEP. Ironically, F11 is not present in the discriminator set.
The jury is out on the expression level of genes, like TFPI:
The ambiguity hidden in the discriminator set of 1072 is shown through another gene related to blood coagulation -TFPI. TFPI has the following counts: This shows slight over-expression in NSCLC, in agreement with Iversen, et al., 1998 [4] , but in contrast to Fei, et al., 2017 [5] , demonstrating that the jury is still out on the levels of many such genes. Decreasing TFPI levels in NSCLC makes more biological sense, since it leads to activation of blood coagulation, which contributes to cancer progression. Additionally, one might also argue about the read counts are moderate, possibly tending to very low levels, where they are not discriminatory.
Conclusion:
This study raises serious doubts on using TEP as a possible 'liquid biopsy' candidate. Essentially, it refutes the hypothesis that platelets carry enough RNA-seq from tumors to make it viable as a diagnostic method. This has been vaguely worded in the TEP-study -'contained undetectable or low levels of these mutant biomarkers' [1] , suggesting that other mRNA ("surrogate signatures") might encode enough information for cancer diagnostics. Here, it is shown in details that most of the 1072 discriminator genes make no sense. The onus lies on the authors of the study to show at least one gene that is differentially regulated in proximity to tumor cells to prove some sort of biological relevance.
Again the statement 'Further validation is warranted to determine the potential of surrogate TEP profiles for blood-based companion diagnostic' is a truism. Further validation is obviously needed -what has been missed is a deeper look at the data presented in the current study. A review found it 'surprising' that although 'the tumor type was the predominant factor for the actual platelet conditioning, tumor metastasis did not significantly impact on them when compared to samples from patients without metastasis' [17] . The excitement surrounding the fact that '2016 marked the first approval of a liquid biopsy test in oncology to assist in patient selection for treatment' [22] should be tempered, and a cautious approach adopted [23, 24] with reports of 'broken promises' [25] .
Circulating mRNA from tumor tissues are not discriminatory -if MET is degraded to such levels in platelets 'educated' by NSCLC tumors, why not other possible mRNA that might have been picked during the same 'class' ? High count genes can only be bona-fide platelet genes, and have no supporting proof of splicing differences (any one gene would suffice). In conclusion, looking past the statistical smoke surrounding "surrogate signatures", one finds no biological relevance.
Materials and methods
A smaller subset of lung cancer samples (DATASET:list.lung.txt,n=24) and healthy (DATASET:list.healthy.txt,n=21) was used from the given 60 NSCLC samples in the TEP study [1] . A kmer-based version (KEATS [26] ) of YeATS [27] [28] [29] [30] [31] was used to obtain gene counts from transcripts in the RNA-seq data. The counts provided are raw reads, and not normalized -but does not alter the criticisms. A BLAST search suffices to demonstrate the absence of MET/EGFR genes in the lung cancer RNA-seq samples.
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